Advanced immunotherapies for glioblastoma: tumor neoantigen vaccines in combination with immunomodulators.

ABSTRACT: Glial-origin brain tumors, including glioblastomas (GBM), have one of the worst prognoses due to their rapid and fatal progression. From an oncological point of view, advances in complete surgical resection fail to eliminate the entire tumor and the remaining cells allow a rapid recurrence, which does not respond to traditional therapeutic treatments. Here, we have reviewed new immunotherapy strategies in association with the knowledge of the immune micro-environment. To understand the best lines for the future, we address the advances in the design of neoantigen vaccines and possible new immune modulators. Recently, the efficacy and availability of vaccine development with different formulations, especially liposome plus mRNA vaccines, has been observed. We believe that the application of

SUBMITTER: Segura-Collar B 

PROVIDER: S-EPMC10171733 | biostudies-literature | 2023 May

REPOSITORIES: biostudies-literature